丽珠医药(深交所代码:000513;香港联交所代码:01513)与纽欧申医药联合宣布,高选择性小分子KCNQ2/3激活剂NS-041已完成Ⅱ期临床试验首例患者给药。这一重要里程碑标志着该创新药物正式进入临床疗效验证阶段,将为局灶性癫痫患者带来新的治疗希望。NS-041Ⅱ期临床试验采用随机、双盲、安慰剂对照、多中心设计,旨在系统评估NS-041片作为局灶性癫痫添加疗法的有效性、安全性、耐受性及群体...
Source Link丽珠医药(深交所代码:000513;香港联交所代码:01513)与纽欧申医药联合宣布,高选择性小分子KCNQ2/3激活剂NS-041已完成Ⅱ期临床试验首例患者给药。这一重要里程碑标志着该创新药物正式进入临床疗效验证阶段,将为局灶性癫痫患者带来新的治疗希望。NS-041Ⅱ期临床试验采用随机、双盲、安慰剂对照、多中心设计,旨在系统评估NS-041片作为局灶性癫痫添加疗法的有效性、安全性、耐受性及群体...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.